electroCore (ECOR) vs EDAP TMS S.A. (FOCL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
EDAP TMS S.A. (FOCL) has outperformed electroCore (ECOR) over the past year, gaining 86.7% versus a gain of 84.7%. Over five years, FOCL leads with a -31.8% price change compared with -36.4% for ECOR. EDAP TMS S.A. is the larger company by market cap ($197.8 million vs $87.1 million), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ECOR | FOCL |
|---|---|---|
| Share price | $9.66 | $4.19 |
| Market cap | $87.09M | $197.84M |
| 1-day change | +1.58% | +1.58% |
| YTD return | +112.04% | +25.38% |
| 1-year return | +84.66% | +86.65% |
| 5-year return | -36.41% | -31.82% |
| EPS (TTM) | $-1.65 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.70 | $6.40 |
| 52-week low | $4.41 | $1.75 |
| Distance from 52-week high | -23.94% | -34.53% |
| Analyst consensus | none | buy |
| Avg. price target upside | +98.45% | +110.02% |
| Average volume | 80.51K | 114.80K |
| Shares outstanding | 9.02M | 47.22M |
| Employees | 83 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDAP TMS S.A. is about 2.3 times larger than electroCore by market value ($197.84M vs $87.09M).
About electroCore
ECOR stock →electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 83 employees
About EDAP TMS S.A.
FOCL stock →EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 289 employees
ECOR vs FOCL FAQ
Which is bigger, electroCore or EDAP TMS S.A.?
EDAP TMS S.A. (FOCL) is larger, with a market capitalization of $197.84M compared with $87.09M for electroCore (ECOR).
Which stock has performed better over the past year, ECOR or FOCL?
FOCL returned +86.65% over the past 12 months, compared with +84.66% for ECOR (price return, excluding dividends). Past performance does not predict future results.
Are electroCore and EDAP TMS S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.